Data Visualization•6 min read•Updated 2026-04-03

    GLP-1 Medication Decision Tree: Which Weight Loss Drug Is Right for You?

    Interactive decision guide to help you choose between semaglutide, tirzepatide, and retatrutide based on your goals, health conditions, budget, and preferences.

    More on Data Visualization

    View all Data Visualization articles

    Sem vs Tir

    Head-to-head comparison

    Which GLP-1 Quiz

    Interactive quiz

    Quick Answer

    For most first-time patients: start with semaglutide ($125/mo). For insulin resistance or aggressive goals: tirzepatide ($125/mo). For maximum results or after plateauing: retatrutide.

    Decision Points

    What is your primary goal?

    Moderate weight loss (10-15%)Semaglutide $99/mo
    Aggressive weight loss (20%+)Tirzepatide $125/mo
    Maximum weight loss (24%+)Retatrutide

    Do you have insulin resistance or PCOS?

    YesTirzepatide (dual GIP/GLP-1 action)
    NoEither semaglutide or tirzepatide

    What is your budget?

    Most affordable optionSemaglutide $125/mo
    Best value per pound lostTirzepatide $125/mo

    Have you tried a GLP-1 before?

    First timeStart with semaglutide
    Plateaued on semaglutideSwitch to tirzepatide
    Plateaued on tirzepatideConsider retatrutide

    Medication Quick Comparison

    Semaglutide

    $99/mo

    • 15-17% weight loss
    • Most studied GLP-1
    • Best for first-timers
    • Most affordable option

    Tirzepatide

    $125/mo

    • 20-22% weight loss
    • Dual GIP/GLP-1 action
    • Best for insulin resistance
    • Best value per pound lost

    Retatrutide

    Ask us

    • 24%+ weight loss
    • Triple agonist (GLP-1/GIP/glucagon)
    • Maximum efficacy
    • For plateaued patients

    Medical Disclaimer: This decision guide is for informational purposes. Your Trimi provider will recommend the best medication based on your complete health profile.

    Frequently Asked Questions

    How do I choose between semaglutide and tirzepatide?

    Consider your budget ($125/mo vs $125/mo), weight loss goals (moderate vs aggressive), and health conditions. Tirzepatide may be better for insulin resistance, PCOS, and higher weight loss targets. Semaglutide has a longer safety track record and is more affordable.

    Who should consider retatrutide?

    Retatrutide may be ideal for patients who have plateaued on semaglutide or tirzepatide, those with very high BMI (40+), patients with fatty liver disease, or those seeking maximum possible weight loss. It works on three receptors instead of one or two.

    Can I switch medications if one doesn't work?

    Yes. Switching between GLP-1 medications is common and safe. If semaglutide produces insufficient results, upgrading to tirzepatide often restarts weight loss. Your Trimi provider can guide the transition protocol.

    Should I start with the cheapest option first?

    Starting with semaglutide ($99/mo) is a reasonable approach for many patients. If results are satisfactory, there's no need to switch. If you need more aggressive weight loss, you can upgrade to tirzepatide ($125/mo) at any time.

    Find Your Best GLP-1 Match

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 8, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    — Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    — Sarah MillerFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Data Visualization

    GLP-1 Protein Calculator: How Much Protein You Need on Semaglutide or Tirzepatide

    Interactive protein calculator designed for GLP-1 medication users. Calculate your daily protein target based on weight, activity level, and weight loss phase.

    10 minRead More
    Data Visualization

    GLP-1 Drug Pipeline Visual: Every Weight Loss Medication in Development (2026)

    Visual map of every GLP-1 and weight loss medication currently in clinical trials, from Phase 1 through FDA approval. See what is coming next after semaglutide and tirzepatide.

    10 minRead More
    Retatrutide

    Retatrutide: Complete Guide

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    10 minRead More
    Retatrutide

    Retatrutide: Complete Guide

    Side-by-side comparison of retatrutide, tirzepatide, and semaglutide: mechanisms, weight loss data, side effects, dosing, cost, and availability in 2026.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started